Briacell Therapeutics

BCTX · TORONTO

$3.44+$0.025 (+0.73%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $3.41

Latest news

Press releaseOct 23, 7:30 AM ETGlobe Newswire
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Press releaseOct 6, 7:30 AM ETGlobe Newswire
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Press releaseSep 14, 7:30 AM ETGlobe Newswire
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
Press releaseSep 11, 8:45 AM ETGlobe Newswire
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
NewsSep 8, 7:35 AM ET
Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Press releaseSep 8, 7:30 AM ETGlobe Newswire
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Press releaseAug 24, 7:30 AM ETGlobe Newswire
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
Press releaseAug 5, 7:30 AM ETGlobe Newswire
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
NewsJul 16, 7:36 AM ET
Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Press releaseJul 16, 7:30 AM ETGlobe Newswire
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
Press releaseJul 15, 7:30 AM ETGlobe Newswire
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
NewsJul 7, 7:32 AM ET
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT
Press releaseMar 31, 4:05 PM ETGlobe Newswire
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
Press releaseFeb 18, 5:30 PM ETGlobe Newswire
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
NewsJan 14, 12:41 PM ETAvi Kapoor
Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November
NewsJan 14, 9:40 AM ETAvi Kapoor
Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings
Press releaseJan 7, 10:32 AM ETPRNewswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Press releaseDec 10, 7:30 AM ETGlobe Newswire
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
NewsDec 10, 5:00 AM ETAvi Kapoor
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
NewsJul 11, 7:32 AM ET
BriaCell Therapeutics Announces Updated Phase 2 Survival Data For Immunotherapy Candidate, Bria-IMT, In Combination With Immune Check Point Inhibitor
Press releaseJul 11, 7:30 AM ETGlobe Newswire
BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
NewsJun 16, 5:12 PM ET
BriaCell Therapeutics Q3 EPS $(1.64) Down From $1.61 YoY
Press releaseJun 2, 7:30 AM ETGlobe Newswire
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Press releaseMay 20, 7:30 AM ETGlobe Newswire
BriaCell CEO Letter to Shareholders
Press releaseMay 1, 11:01 AM ETPRNewswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
NewsApr 25, 5:38 AM ETAvi Kapoor
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
NewsApr 23, 7:01 AM ETAvi Kapoor
Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
NewsFeb 4, 5:12 AM ETAvi Kapoor
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
NewsJan 6, 5:38 AM ETAvi Kapoor
Why Smart Share Global Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
NewsDec 12, 5:41 AM ETAvi Kapoor
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Press releaseDec 2, 10:18 AM ETPRNewswire
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
NewsNov 26, 8:02 AM ET
BriaCell 2024 SABCS Spotlight Poster To Showcase Overall Survival Data Across All Patient Subtypes In Metastatic Breast Cancer; Median Overall Survival Of 13.4 Months Exceeds Historical Controls. Phase 2 Final Median Overall Survival Calculation Is Pending, As Many Patients Remain Alive
Press releaseNov 26, 7:50 AM ETGlobe Newswire
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
Press releaseOct 22, 7:50 AM ETGlobe Newswire
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
NewsOct 2, 6:59 AM ETAvi Kapoor
Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
NewsSep 11, 2:30 PM ETAvi Kapoor
Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase
NewsSep 11, 12:13 PM ETAvi Kapoor
Crude Oil Surges 2.5%; Rentokil Initial Shares Plunge
NewsSep 11, 9:47 AM ETAvi Kapoor
Dow Tumbles 350 Points; US Inflation Rate Slows In August
NewsSep 11, 8:39 AM ET
Market-Moving News for September 11th
Press releaseJul 18, 7:56 AM ETGlobe Newswire
BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs

Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November

Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings

How $594B in Precision Tech is Cracking the Metastatic Cancer Code

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

BriaCell Therapeutics Announces Updated Phase 2 Survival Data For Immunotherapy Candidate, Bria-IMT, In Combination With Immune Check Point Inhibitor

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

BriaCell Therapeutics Q3 EPS $(1.64) Down From $1.61 YoY

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

BriaCell CEO Letter to Shareholders

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Why Smart Share Global Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

BriaCell 2024 SABCS Spotlight Poster To Showcase Overall Survival Data Across All Patient Subtypes In Metastatic Breast Cancer; Median Overall Survival Of 13.4 Months Exceeds Historical Controls. Phase 2 Final Median Overall Survival Calculation Is Pending, As Many Patients Remain Alive

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

Why JD.com Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Nasdaq Surges Over 200 Points; US Crude Oil Stocks Increase

Crude Oil Surges 2.5%; Rentokil Initial Shares Plunge

Dow Tumbles 350 Points; US Inflation Rate Slows In August

Market-Moving News for September 11th

BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer